A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: Effectiveness on white blood cell cystine levels and comparison of safety

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 7, 2012, Pages 1112-1120

  Langman, Craig B ^a   Greenbaum, Larry A ^b   Sarwal, Minnie ^c   Grimm, Paul ^c   Niaudet, Patrick ^d   Deschênes, Georges ^e   Cornelissen, Elisabeth ^f   Morin, Denis ^g   Cochat, Pierre ^h   Matossian, Debora ^a   Gaillard, Segolene ⁱ   Bagger, Mary Jo ^j   Rioux, Patrice ^j  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ INSERM   (France)

^j Raptor Pharmaceutical Corporation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTINE; MERCAPTAMINE; PROTON PUMP INHIBITOR; RP 103; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTINOSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; LEUKOCYTE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; METABOLIC DISORDER; MORNING DOSAGE; MUSCULOSKELETAL DISEASE; NEPHROPATHIC CYSTINOSIS; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VASCULAR DISEASE;

ADOLESCENT; ADULT; CHILD; CROSS-OVER STUDIES; CYSTEAMINE; CYSTINE; CYSTINOSIS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LEUKOCYTES; MALE; NEPHROTIC SYNDROME; YOUNG ADULT;

EID: 84862844173     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12321211     Document Type: Article

References (35)

1. Forestier L, Jean G, Attard M, Cherqui S, Lewis C, Van't Hoff W, Broyer M, Town M, Antignac C: Molecular characterization of CTNS deletions in nephropathic cystinosis: Development of a PCR-based detection assay. AmJ Hum Genet 65: 353-359, 1999
2. Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, Van't Hoff W, Antignac C: A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nat Genet 18: 319-324, 1998
3. Kalatzis V, Cohen-Solal L, Cordier B, Frishberg Y, Kemper M, Nuutinen EM, Legrand E, Cochat P, Antignac C: Identification of 14 novel CTNS mutations and characterization of seven splice site mutations associated with cystinosis. Hum Mutat 20: 439-446, 2002
4. Wilmer MJ, Emma F, Levtchenko EN: The pathogenesis of cystinosis: Mechanisms beyond cystine accumulation. Am J Physiol Renal Physiol 299: F905-F916, 2010
5. Seegmiller JE, Friedmann T, Harrison HE, Wong V, Schneider JA: Cystinosis. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 68: 883-905, 1968
6. Mahoney CP, Striker GE, Hickman RO, Manning GB, Marchioro TL: Renal transplantation for childhood cystinosis. N Engl J Med 283: 397-402, 1970
7. Schneider JA, Schulman JD: Cystinosis: Areview. Metabolism 26: 817-839, 1977
8. Gahl WA, Schneider JA, Thoene JG, Chesney R: Course of nephropathic cystinosis after age 10 years. J Pediatr 109: 605-608, 1986
9. Kleta R, Kaskel F, Dohil R, Goodyer P, Guay-Woodford LM, Harms E, Ingelfinger JR, Koch VH, Langman CB, Leonard MB, Mannon RB, Sarwal M, Schneider JA, Skovby F, Sonies BC, Thoene JG, Trauner DA, Gahl WA; NIH Office of Rare Diseases: First NIH/Office of Rare Diseases Conference on Cystinosis: Past, present, and future. Pediatr Nephrol 20: 452-454, 2005
10. GahlWA, Tietze F, Butler JD, Schulman JD: Cysteamine depletes cystinotic leucocyte granular fractions of cystine by the mechanism of disulphide interchange. Biochem J 228: 545-550, 1985
11. GrecoM, Brugnara M, Zaffanello M, Taranta A, Pastore A, Emma F: Long-term outcome of nephropathic cystinosis: A 20-year single-center experience. Pediatr Nephrol 25: 2459-2467, 2010
12. Gahl WA, Balog JZ, Kleta R: Nephropathic cystinosis in adults: Natural history and effects of oral cysteamine therapy. Ann Intern Med 147: 242-250, 2007
13. Kleta R, Bernardini I, Ueda M, Varade WS, Phornphutkul C, Krasnewich D, Gahl WA: Long-term follow-up of well-treated nephropathic cystinosis patients. J Pediatr 145: 555-560, 2004
14. Levtchenko EN, van Dael CM, de Graaf-Hess AC, Wilmer MJ, van den Heuvel LP, Monnens LA, Blom HJ: Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 21: 110-113, 2006
15. Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BAL: Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr 156: 71-75. e71-73, 2010
16. Dohil R, Gangoiti JA, Cabrera BL, Fidler M, Schneider JA, Barshop BA: Long-term treatment of cystinosis in children with twice-daily cysteamine. J Pediatr 156: 823-827, 2010
17. Schwartz GJ, Work DF: Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4: 1832-1843, 2009
18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serumcreatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247-254, 2006
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951
20. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985
21. Powell KL, Langman CB: An unexpected problem in the clinical assessment of cystinosis. Pediatr Nephrol 27: 687-688, 2012
22. Northrop Grumman Corporation: MedDRA: Medical Dictionary for Regulatory Activities. Available at: http://www.meddramsso. com/index.asp. Accessed April 19, 2012
23. Cystagon [package insert]. Mylan Pharmaceuticals, Canonsburg, PA, 2007
24. International Conference on Harmonisation: Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance, 1996. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM073122.pdf. Accessed April 19, 2012
25. Sonies BC, Almajid P, Kleta R, Bernardini I, Gahl WA: Swallowing dysfunction in 101 patients with nephropathic cystinosis: Benefit of long-term cysteamine therapy. Medicine (Baltimore) 84: 137-146, 2005
26. Ueda M, O'Brien K, Rosing DR, Ling A, Kleta R, McAreavey D, Bernardini I, Gahl WA: Coronary artery and other vascular calcifications in patients with cystinosis after kidney transplantation. Clin J Am Soc Nephrol 1: 555-562, 2006
27. Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA: Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab 80: 3257-3261, 1995
28. Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC: Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: Report of a case and review of the literature. Surv Ophthalmol 52: 97-105, 2007
29. BesouwM, Blom H, Tangerman A, de Graaf-Hess A, Levtchenko E: The origin of halitosis in cystinotic patients due to cysteamine treatment. Mol Genet Metab 91: 228-233, 2007
30. Besouw M, Levtchenko E: Growth retardation in children with cystinosis. Minerva Pediatr 62: 307-314, 2010
31. BesouwMT, Bowker R, Dutertre JP, Emma F, GahlWA, GrecoM, LilienMR, McKiernan J, Nobili F, Schneider JA, Skovby F, van den Heuvel LP, Van't Hoff WG, Levtchenko EN: Cysteamine toxicity in patients with cystinosis. J Pediatr 159: 1004-1011, 2011
32. Dohil R, Newbury RO, Sellers ZM, Deutsch R, Schneider JA: The evaluation and treatment of gastrointestinal disease in children with cystinosis receiving cysteamine. J Pediatr 143: 224-230, 2003
33. Dohil R, Fidler M, Barshop BA, Gangoiti J, Deutsch R, Martin M, Schneider JA: Understanding intestinal cysteamine bitartrate absorption. J Pediatr 148: 764-769, 2006
34. Gangoiti JA, Fidler M, Cabrera BL, Schneider JA, Barshop BA, Dohil R: Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: A pilot study. Br J Clin Pharmacol 70: 376-382, 2010
35. US Food and Drug Administration: FDA Drug Safety Communication: Low Magnesium Levels Can Be Associated with Long-Term Use of Proton Pump Inhibitor Drugs (PPIs), Silver Spring, MD, US Food and Drug Administration, 2011